Grundlæggende statistik
| LEI | 54930074G13LHWJT2323 |
| CIK | 1701108 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Spero Therapeutics, Inc.
SEC Filings (Chronological Order)
Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.
| August 12, 2025 |
Calculation of Filing Fee Tables S-8 Spero Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.001 per share Other 3,000,000 $ 2.19 $ 6,570,000.00 0.0001531 $ 1,005.87 Total Of |
|
| August 12, 2025 |
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update • PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC) • Spero, along with its development partner, GSK, plans to submit data from the PIVO |
|
| August 12, 2025 |
EX-99.2 Corporate Presentation August 2025 Exhibit 99.2 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, statements regarding, among other things, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr gener |
|
| August 12, 2025 |
2017 Stock Incentive Plan, as amended. Exhibit 10.1 SPERO THERAPEUTICS, INC. AMENDED AND RESTATED 2017 STOCK INCENTIVE PLAN (As Amended on June 12, 2025) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2017 Stock Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act o |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THER |
|
| August 12, 2025 |
As filed with the Securities and Exchange Commission on August 12, 2025 S-8 As filed with the Securities and Exchange Commission on August 12, 2025 Registration No. |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| May 28, 2025 |
Spero Therapeutics and GSK Announce EX-99.1 Exhibit 99.1 Spero Therapeutics and GSK Announce PIVOT-PO phase 3 study for tebipenem HBr stopped early for efficacy following review by Independent Data Monitoring Committee • If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) • An estimated 2.9 million cases of cUTIs are treated annually in the US1 wi |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2025 |
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update Exhibit 99.1 Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update • Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025 • Existing cash, together with earned development milestones from GSK, pr |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| May 13, 2025 |
Exhibit 10.10 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is made and entered into this 28 day of April, 2025 by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Esther Rajavelu (“Executive”). WHEREAS, Executive is currently employed by Company as its President and Chief Executive Offic |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THE |
|
| May 13, 2025 |
Separation Agreement, dated April 28, 2025, by and between the Registrant and Satyavrat Shukla Exhibit 10.5 April 28, 2025 Mr. Satyavrat Shukla 125 Lyman Road Milton, MA 02186 Dear Mr. Shukla: As was discussed with you, your employment with Spero Therapeutics, Inc. (the “Company”) is ending. This letter is to summarize the terms of the separation package that the Company is offering you as a result of your separation from employment. Please read this Agreement (the “Agreement”), which inclu |
|
| April 28, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6 |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by |
|
| April 28, 2025 |
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer EX-99.1 Exhibit 99.1 Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer CAMBRIDGE, Mass., April 28, 2025 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve |
|
| March 27, 2025 |
2019 Inducement Equity Incentive Plan, as amended Exhibit 10.4 SPERO THERAPEUTICS, INC. 2019 Inducement Equity Incentive Plan (As Amended on March 6, 2024) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to ac |
|
| March 27, 2025 |
Exhibit 10.12 November 13, 2024 Satyavrat Shukla 125 Lyman Road Milton, MA 02186 Dear Satyavrat: We would like to sincerely thank you for your many contributions to Spero Therapeutics, Inc. (“Spero” or the “Company”) to date. We have important strategic goals to accomplish as we continue to progress our ongoing programs and, in recognition of the key role you play for the Company, I am pleased to |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38266 SPERO THERAPEUT |
|
| March 27, 2025 |
Exhibit 10.22 November 13, 2024 Esther Rajavelu 515 East 86th Street Apt. 2105 New York, NY 10028 Dear Esther: We would like to sincerely thank you for your many contributions to Spero Therapeutics, Inc. (“Spero” or the “Company”) to date. We have important strategic goals to accomplish as we continue to progress our ongoing programs and, in recognition of the key role you play for the Company, I |
|
| March 27, 2025 |
Exhibit 99.1 Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update • Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025 • Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of |
|
| March 27, 2025 |
Exhibit 10.28 AMENDED & RESTATED CONSULTING AGREEMENT This Amended and Restated Consulting Agreement (the “Agreement”) is dated January 29, 2025 and is effective as of the date of the last signature hereto (the “Effective Date”) by and between Spero Therapeutics, Inc., with offices located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, together with its subsidiaries and affiliates ( |
|
| March 27, 2025 |
Clawback Policy, effective as of November 12, 2023 CLAWBACK POLICY Effective November 12, 2023 I. Introduction The Board of Directors (“Board) of Spero, Therapeutics, Inc. (“Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted |
|
| March 27, 2025 |
Exhibit 10.19 November 13, 2024 Timothy Keutzer 3 Nicole Lane Littleton, MA 01460 Dear Timothy: We would like to sincerely thank you for your many contributions to Spero Therapeutics, Inc. (“Spero” or the “Company”) to date. We have important strategic goals to accomplish as we continue to progress our ongoing programs and, in recognition of the key role you play for the Company, I am pleased to o |
|
| March 27, 2025 |
AMENDMENT 2 TO EXCLUSIVE LICENSE AGREEMENT This Amendment 2 (“Amendment 2”) entered into as of December 20, 2023 (“Amendment 2 Effective Date”), by and between Spero Therapeutics, Inc. |
|
| March 27, 2025 |
AMENDMENT 1 TO EXCLUSIVE LICENSE AGREEMENT This Amendment 1 (“Amendment 1”) entered into as of July 4 2023 (“Amendment 1 Effective Date”), by and between Spero Therapeutics, Inc. |
|
| March 27, 2025 |
CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is dated February 9, 2024 and is effective as of March 6, 2024 (the “Effective Date”) by and between Spero Therapeutics, Inc. |
|
| March 27, 2025 |
Separation Agreement, dated February 9, 2024, by and between the Registrant and Tamara Joseph February 9, 2024 Ms. Tamara Joseph 210 Pleasant Street Arlington, MA 02476 Dear Tamara: As was discussed with you, your employment with Spero Therapeutics, Inc. (the "Company") is ending. This letter is to summarize the terms of the separation package that the Company is willing to offer you as a result of your separation from employment. Please read this letter agreement (the “Letter Agreement”), |
|
| March 27, 2025 |
Spero Therapeutics, Inc. Insider Trading Policy, effective as of June 5, 2023 Exhibit 19.1 Last updated June 5, 2023 SPERO THERAPEUTICS, INC. INSIDER TRADING POLICY 1. BACKGROUND AND PURPOSE 1.1 Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (a “Director”) or employee of Spero Therapeutics, Inc. (the “Company”) (including its subsidiaries) from purchasing or selling Company securities on the basis of material nonpu |
|
| March 27, 2025 |
Non-Employee Director Compensation Policy, as amended SPERO THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Last amended September 15, 2023) The Board of Directors (“Board”) of Spero Therapeutics, Inc. (“Company”) has approved the following Non-Employee Director Compensation Policy (“Policy”), which establishes compensation to be paid to non-employee directors of the Company to provide an inducement to obtain and retain the services of |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| January 10, 2025 |
Corporate Presentation January 2025 EX-99.1 Exhibit 99.1 Corporate Presentation January 2025 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, statements regarding, among other things, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr gen |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| January 10, 2025 |
Interim Period Agreement, dated January 10, 2025, between the Company and Ms. Rajavelu. EX-10.2 Exhibit 10.2 675 Massachusetts Avenue, 14th Floor Cambridge, MA 02139 January 10, 2025 Esther Rajavelu Re: Interim Period Agreement Dear Esther: The Board of Directors (the “Board”) of Spero Therapeutics, Inc., a Delaware corporation (the “Company”), has asked you to serve, and you have agreed to serve, as the interim President and Chief Executive Officer of the Company during the peri |
|
| January 10, 2025 |
Interim Period Agreement, dated January 10, 2025, between the Company and Mr. Shukla. EX-10.1 Exhibit 10.1 675 Massachusetts Avenue, 14th Floor Cambridge, MA 02139 January 10, 2025 Satayavrat Shukla Re: Interim Period Agreement Dear Sath: This letter confirms that you and Spero Therapeutics, Inc., a Delaware corporation (“Company”) have agreed that you will be placed on an administrative leave, commencing January 10, 2025. The Company and its Board of Directors (the “Board”) be |
|
| January 10, 2025 |
EX-99.2 Exhibit 99.2 Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company’s Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipen |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
Execution Version AMENDMENT 4 TO Exclusive License Agreement This Amendment 4 (“Amendment 4”) entered into as of the last date of the signatures below (“Amendment 4 Effective Date”), by and between Spero Therapeutics, Inc. |
|
| November 14, 2024 |
Separation Agreement, dated July 30, 2024, by and between the Registrant and Kama Hamed. Exhibit 10.2 July 30, 2024 Kamal Hamed 16 Pony Lane Flemington, New Jersey 08822 Dear Kamal: As was discussed with you, your employment with Spero Therapeutics, Inc. (the “Company”) is ending. This letter is to summarize the terms of the separation package that the Company is willing to offer you as a result of your separation from employment. Please read this letter agreement (the “Letter Agreeme |
|
| November 14, 2024 |
Exhibit 10.3 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is dated August 1, 2024 and is effective as of August 5, 2024 (the “Effective Date”) by and between Spero Therapeutics, Inc., with offices located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, together with its subsidiaries and affiliates (collectively, “Spero”) and John C. Pottage, Jr., M.D. (“Consultant |
|
| November 14, 2024 |
Exhibit 99.1 Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025 Reiterate cash runway into mid-2026; Q3 2024 ending cash balance of $76.3M CAMBRIDGE, Mass., November 14, 2024 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutica |
|
| November 14, 2024 |
SPRO / Spero Therapeutics, Inc. / Anson Funds Management LP - SC 13G/A Passive Investment SC 13G/A 1 d868021dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No.1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84833T103 (CUS |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO |
|
| November 14, 2024 |
Consulting Agreement, effective as of August 29, 2024, by and between the Registrant and Kamal Hamed Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is dated August 7, 2024, and is effective as of August 29, 2024 (the “Effective Date”) by and between Spero Therapeutics, Inc., with offices located at 675 Massachusetts Avenue, 14th Floor, Cambridge, MA 02139, together with its subsidiaries and affiliates (collectively, “Spero”) and Kamal Hamed (“Consultant”). Spero and |
|
| October 29, 2024 |
Corporate Presentation October 2024 Exhibit 99.2 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the future development and commercialization of SPR720 and SPR206; the potential number of patients who could be treated by SPR 720 and tebipenem HBr and market demand for S |
|
| October 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| October 29, 2024 |
Exhibit 99.1 Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients Phase 3 PIVOT-PO trial of tebipenem HBr remains on track for enrollment completion in 2H 202 |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| September 10, 2024 |
EX-99.1 Exhibit 99.1 Corporate Presentation Sept 2024 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the future development and commercialization of SPR720 and SPR206; the potential number of patients who could be treated by SPR 720 and tebipenem HBr and market demand |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Spero Therapeutics, Inc. |
|
| August 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THER |
|
| August 5, 2024 |
Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update • Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024 • New SPR720 in-vitro resistance data to be presented at IDWeek 2024 conference in October • Company an |
|
| August 5, 2024 |
Exhibit 99.2 Corporate Presentation August 2024 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential regulatory path forward for tebipenem HBr and the potential approval of tebipenem HBr by the U.S. Food and Drug Administration (FDA) and the timing thereof; the |
|
| August 5, 2024 |
As filed with the Securities and Exchange Commission on August 5, 2024 As filed with the Securities and Exchange Commission on August 5, 2024 Registration No. |
|
| June 3, 2024 |
2017 Stock Incentive Plan, as amended. Exhibit 10.1 SPERO THERAPEUTICS, INC. AMENDED AND RESTATED 2017 STOCK INCENTIVE PLAN As Amended on May 29, 2024 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2017 Stock Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on i |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THE |
|
| May 15, 2024 |
Execution Version AMENDMENT 3 TO EXCLUSIVE LICENSE AGREEMENT This Amendment 3 (“Amendment 3”) entered into as of the last date of the signatures below (“Amendment 3 Effective Date”), by and between Spero Therapeutics, Inc. |
|
| May 15, 2024 |
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update Exhibit 99.1 Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update • On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 • Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI • Received FDA Fast Trac |
|
| May 15, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
Employment Agreement, dated October 31, 2023 by and between the Registrant and Esther Rajavelu Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made and entered into this 31st day of October, 2023 (the “Effective Date”) by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Esther Rajavelu (“Executive”). WHEREAS, Executive and Company desire to set forth the terms and conditions for the employment of Executive by |
|
| April 16, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2024 |
Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 March 20, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Cindy Polynice RE: Spero Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-277998 Request for Acceleration of Effectiveness Ladies |
|
| March 15, 2024 |
Form of Subordinated Indenture EX-4.11 Exhibit 4.11 SPERO THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13(a) 311(b). 7.13(b) 311(c). Inapplicable 312(a) 5.02(a) 312(b). 5.02(b) 312(c). 5.02(c) 313(a). 5.04(a) 313(b). 5.0 |
|
| March 15, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Spero Therapeutics, Inc. |
|
| March 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-3 Spero Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initia |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 15, 2024 |
As filed with the Securities and Exchange Commission on March 15, 2024 S-8 As filed with the Securities and Exchange Commission on March 15, 2024 Registration No. |
|
| March 15, 2024 |
EX-4.10 Exhibit 4.10 SPERO THERAPEUTICS, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as Amended Section of Indenture 310(a). 7.09 310(b). 7.08 7.10 310(c). Inapplicable 311(a). 7.13 (a) 311(b). 7.13 (b) 311(c). Inapplicable 312(a) 5.02 (a) 312(b). 5.02 (b) 312(c). 5.02 (c) 313(a). 5.04 (a) 313(b). 5.0 |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2024 |
AMENDMENT 1 TO EXCLUSIVE LICENSE AGREEMENT This Amendment 1 (“Amendment 1”) entered into as of July 4 2023 (“Amendment 1 Effective Date”), by and between Spero Therapeutics, Inc. |
|
| March 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38266 SPERO THERAPEUT |
|
| March 13, 2024 |
Consulting Agreement, dated February 9, 2024, by and between the Registrant and Tamara Joseph CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is dated February 9, 2024 and is effective as of March 6, 2024 (the “Effective Date”) by and between Spero Therapeutics, Inc. |
|
| March 13, 2024 |
AMENDMENT 2 TO EXCLUSIVE LICENSE AGREEMENT This Amendment 2 (“Amendment 2”) entered into as of December 20, 2023 (“Amendment 2 Effective Date”), by and between Spero Therapeutics, Inc. |
|
| March 13, 2024 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update • On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024 • Initiated enrollment in PIVOT-PO, a pivotal Phase 3 clinical trial of oral Tebipenem HBr in cUTI |
|
| March 13, 2024 |
Separation Agreement, dated February 9, 2024, by and between the Registrant and Tamara Joseph February 9, 2024 Ms. Tamara Joseph 210 Pleasant Street Arlington, MA 02476 Dear Tamara: As was discussed with you, your employment with Spero Therapeutics, Inc. (the "Company") is ending. This letter is to summarize the terms of the separation package that the Company is willing to offer you as a result of your separation from employment. Please read this letter agreement (the “Letter Agreement”), |
|
| March 13, 2024 |
Clawback Policy, effective as of November 12, 2023 CLAWBACK POLICY Effective November 12, 2023 I. Introduction The Board of Directors (“Board) of Spero, Therapeutics, Inc. (“Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted |
|
| March 13, 2024 |
Non-Employee Director Compensation Policy, as amended SPERO THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Last amended September 15, 2023) The Board of Directors (“Board”) of Spero Therapeutics, Inc. (“Company”) has approved the following Non-Employee Director Compensation Policy (“Policy”), which establishes compensation to be paid to non-employee directors of the Company to provide an inducement to obtain and retain the services of |
|
| March 13, 2024 |
2019 Inducement Equity Incentive Plan, as amended Exhibit 10.4 SPERO THERAPEUTICS, INC. 2019 Inducement Equity Incentive Plan (As Amended on March 6, 2024) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to ac |
|
| February 14, 2024 |
EX-99.1 2 d764526dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value, of Spero Therapeutics, Inc., a Delaware corpo |
|
| February 14, 2024 |
SPRO / Spero Therapeutics, Inc. / Anson Funds Management LP - SC 13G Passive Investment SC 13G 1 d764526dsc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) (Amendment No. ) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84833T103 (CUSIP Nu |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| January 8, 2024 |
Corporate Presentation January 8, 2024 Exhibit 99.1 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential regulatory path forward for tebipenem HBr and the potential approval of tebipenem HBr by the U.S. Food and Drug Administration (FDA) and the timing thereof; |
|
| January 5, 2024 |
Exhibit 99.1 Spero Therapeutics Provides Corporate Update and 2024 Outlook In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients Initiated dosing in PIVOT-PO Phase 3 trial for tebipenem HBr in cUTI patients. Entitled to receive $95 million in development milestones, payable over two years, as part of the GSK license agreem |
|
| January 5, 2024 |
Corporate Presentation January 2024 Exhibit 99.2 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential regulatory path forward for tebipenem HBr and the potential approval of tebipenem HBr by the U.S. Food and Drug Administration (FDA) and the timing thereof; th |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2024 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 SPERO THERAPEUTICS, INC. (Exact Name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| January 2, 2024 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces First Patient First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections $95 million in development milestones payable over two years, as part of GSK license agreement CAMBRIDGE, Mass., January 2, 2024 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focu |
|
| November 13, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Spero Therapeutics, Inc. |
|
| November 13, 2023 |
Amended and Restated Bylaws of the Registrant AMENDED AND RESTATED BYLAWS OF SPERO THERAPEUTICS, INC. TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Nomination of Directors 3 1.11 Notice of Business at Annual Meetings 7 1.12 Conduct of Meetings 9 1 |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 S-8 As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 13, 2023 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., November 13, 2023 — Spero Therapeutics, Inc. (Nasdaq: SPRO |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO |
|
| November 13, 2023 |
As filed with the Securities and Exchange Commission on November 13, 2023 S-8 As filed with the Securities and Exchange Commission on November 13, 2023 Registration No. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| November 13, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Spero Therapeutics, Inc. |
|
| November 13, 2023 |
2019 Inducement Equity Incentive Plan, as amended. EX-4.5 Exhibit 4.5 SPERO THERAPEUTICS, INC. 2019 Inducement Equity Incentive Plan (As Amended on October 30, 2023) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated po |
|
| November 1, 2023 |
Exhibit 99.1 Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer Ms. Rajavelu brings over two decades of experience in the life sciences sector focused on strategic growth, financing, M&A, and investor relations. CAMBRIDGE, Mass., November 1, 2023 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused |
|
| November 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2023 SPERO THERAPEUTICS, INC. (Exact Name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| October 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incor |
|
| October 16, 2023 |
Exhibit 3.1 CERTIFICATE OF CORRECTION OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF SPERO THERAPEUTICS, INC. Spero Therapeutics, Inc., a Delaware corporation (the “Corporation”), pursuant to Section 103(f) of the Delaware General Corporation Law (“DGCL”), hereby certifies that: FIRST: The name of the Corporation is Spero Therapeutics, Inc. SECOND: That a Certificate of Amendm |
|
| October 10, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED OF SPERO THERAPEUTICS, INC. It is hereby certified that: FIRST: The name of the corporation is Spero Therapeutics, Inc. (the “Corporation”). SECOND: The Amended and Restated Certificate of Incorporation of the Corporation, filed on November 6, 2017, as amended by that certain Certificate of Amendm |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| October 10, 2023 |
2017 Stock Incentive Plan, as amended Exhibit 10.1 SPERO THERAPEUTICS, INC. AMENDED AND RESTATED 2017 STOCK INCENTIVE PLAN (As Amended on October 5, 2023) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2017 Stock Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act |
|
| September 1, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 22, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 10, 2023 |
Consulting Agreement, dated June 12, 2023, by and between the Registrant and Danforth Advisors, LLC CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made effective as of July 15, 2023 (the “Effective Date”), by and between Spero Therapeutics, Inc. |
|
| August 10, 2023 |
TRANSITION AND SEPARATION AGREEMENT This Separation and Transition Agreement (the “Agreement”) is made and entered into this 13th day of June, 2023 (the “Execution Date”) by and between Spero Therapeutics, Inc. |
|
| August 10, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Spero Therapeutics, Inc. |
|
| August 10, 2023 |
Consulting Agreement, dated June 13, 2023, by and between the Registrant and Ankit Mahadevia, M.D. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is dated June 13, 2023, and is effective as of August 1, 2023, (the “Effective Date”) by and between Spero Therapeutics, Inc. |
|
| August 10, 2023 |
As filed with the Securities and Exchange Commission on August 10, 2023 S-8 As filed with the Securities and Exchange Commission on August 10, 2023 Registration No. |
|
| August 10, 2023 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update SPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and CEO, Effective August 1 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Augus |
|
| August 10, 2023 |
Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan, as amended Exhibit 4.6 Option No. SPERO THERAPEUTICS, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2019 Inducement Equity Incentive Plan (As Amended) 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: Non-Qualified Stock Option 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Dat |
|
| August 10, 2023 |
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”) is made and entered into this 1st day of August, 2023 by and between Spero Therapeutics, Inc. |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THER |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| August 10, 2023 |
2019 Inducement Equity Incentive Plan, as amended. EX-4.5 Exhibit 4.5 SPERO THERAPEUTICS, INC. 2019 Inducement Equity Incentive Plan (As Amended on July 27, 2023) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power |
|
| August 10, 2023 |
Form of Restricted Stock Unit Agreement under the 2019 Inducement Equity Incentive Plan, as amended Exhibit 4.7 Restricted Stock Unit No. SPERO THERAPEUTICS, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2019 Inducement Equity Incentive Plan (As Amended) 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restricted S |
|
| July 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| July 31, 2023 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Spero to receive $30 million development milestone payment from GSK CAMBRIDGE, Mass., July 31, 2023 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage |
|
| June 14, 2023 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023 Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors CAMBRIDGE, Mass. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THE |
|
| May 11, 2023 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces First Quarter 2023 Operating Results and Provides a Business Update Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD) on track for top line data readout in 1H 2024 Update on status of Special Protocol Assessment agreement for tebipenem HBr program expected mid-year 2023; initiation of Phase 3 trial in complicated ur |
|
| May 11, 2023 |
Exhibit 10.1 SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Second Amendment to Executive Employment Agreement (the “Second Amendment”) is made and entered effective as of February 1, 2023 (the “Effective Date”) by and between Spero Therapeutics, Inc., a Delaware corporation (“Company”), and Timothy Keutzer (“Executive”) (each a “Party” and collectively, the “Parties”). BACKGROUND WHEREAS |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| March 30, 2023 |
Form of Restricted Stock Unit Agreement under the 2019 Inducement Equity Incentive Plan, as amended Restricted Stock Unit No. SPERO THERAPEUTICS, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2019 Inducement Equity Incentive Plan (As Amended on December 22, 2022) 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Res |
|
| March 30, 2023 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Spero Therapeutics, Inc. (the “Company” or “we”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). DESCRIPTION OF COMMON STOCK We are authorized to issue 120,000,000 shares of commo |
|
| March 30, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Spero Therapeutics, Inc. |
|
| March 30, 2023 |
2019 Inducement Equity Incentive Plan, as amended SPERO THERAPEUTICS, INC. 2019 Inducement Equity Incentive Plan (As Amended on December 22, 2022) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its |
|
| March 30, 2023 |
EX-99.1 Exhbit 99.1 Spero Therapeutics Announces Fourth Quarter and Full Year 2022 Operating Results and Provides Business Update Initiated proof-of-concept Phase 2 trial of SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); top line data expected in 1H 2024 Exclusive license agreement with GSK for tebipenem HBr provided Spero with $66 million upfront, a $9 million direct equity in |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38266 SPERO THERAPEUT |
|
| March 30, 2023 |
As filed with the Securities and Exchange Commission on March 30, 2023 S-8 As filed with the Securities and Exchange Commission on March 30, 2023 Registration No. |
|
| March 30, 2023 |
Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan, as amended Option No. SPERO THERAPEUTICS, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2019 Inducement Equity Incentive Plan (As Amended on December 22, 2022) 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: Non-Qualified Stock Option 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expir |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2023 |
SPRO / Spero Therapeutics Inc / Aquilo Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 84833T103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2023 |
SC 13G/A 1 sc13ga507422spro02142023.htm AMENDMENT NO. 5 TO THE SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 5)1 Spero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 |
|
| February 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| January 20, 2023 |
SPRO / Spero Therapeutics Inc / GLAXOSMITHKLINE PLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 84833T 10 3 (CUSIP Num |
|
| January 9, 2023 |
Spero Therapeutics, Inc. A Leader in Infectious and Rare Diseases SPR720: Potential Novel, First Line, Oral Therapy for NTM Infections Strong Balance Sheet Supported by World Class Partnerships for Tebipenem HBr, SPR206 NTM = non-tuberculous mycobacterial; MDR = multidrug resistant infections; Tebipenem HBr = tebipenem pivoxil hydrobromide (formerly SPR994), 1. CHEST Foundation, About Nontuberculo |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| January 9, 2023 |
Corporate Presentation January 2023 Exhibit 99.1 Forward-looking Statement This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential regulatory path forward for tebipenem HBr and the potential approval of tebipenem HBr by the U.S. Food and Drug Administration (FDA) and the timing thereof; th |
|
| November 14, 2022 |
Exhibit 10.6 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to Executive Employment Agreement (the ?Amendment?) is made and entered effective as of November 10, 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc., a Delaware corporation (?Company?), and Ankit Mahadevia, M.D. (?Executive?) (each a ?Party? and collectively, the ?Parties?). BACKGROUND WHEREAS, Company curr |
|
| November 14, 2022 |
Exhibit 10.8 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to Executive Employment Agreement (the ?Amendment?) is made and entered effective as of November 10, 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc., a Delaware corporation (?Company?), and Kamal Hamed, M.D., M.P.H., M.B.A. (?Executive?) (each a ?Party? and collectively, the ?Parties?). BACKGROUND WHEREAS, |
|
| November 14, 2022 |
Exhibit 10.7 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to Executive Employment Agreement (the ?Amendment?) is made and entered effective as of November 10, 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc., a Delaware corporation (?Company?), and Satyavrat Shukla (?Executive?) (each a ?Party? and collectively, the ?Parties?). BACKGROUND WHEREAS, Company currently |
|
| November 14, 2022 |
SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this ?Agreement?) dated as of September 21, 2022 (the ?Effective Date?) is made by and between Spero Therapeutics, Inc. |
|
| November 14, 2022 |
AMENDMENT 1 TO Consulting Agreement This Amendment 1 (?Amendment 1?) is dated August 4, 2022 and is effective as of July 3, 2022 (?Amendment 1 Effective Date?), by and between Spero Therapeutics, Inc. |
|
| November 14, 2022 |
Exhibit 10.9 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to Executive Employment Agreement (the ?Amendment?) is made and entered effective as of November 10, 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc., a Delaware corporation (?Company?), and Timothy Keutzer (?Executive?) (each a ?Party? and collectively, the ?Parties?). BACKGROUND WHEREAS, Company currently |
|
| November 14, 2022 |
Exhibit 99.1 Spero Therapeutics Announces Third Quarter 2022 Operating Results and Provides Business Update Entered into and closed exclusive license agreement with GSK for tebipenem HBr, pursuant to which Spero receives $66 million upfront, and a $9 million direct equity investment in Spero shares of common stock, with potential for future milestone payments and tiered royalties Initiation of a p |
|
| November 14, 2022 |
SPRO / Spero Therapeutics Inc / GLAXOSMITHKLINE PLC - SCHEDULE 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 7)* SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 84833T 10 3 (CUSIP Num |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2022 |
As filed with the Securities and Exchange Commission on November 14, 2022 As filed with the Securities and Exchange Commission on November 14, 2022 Registration No. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO |
|
| November 14, 2022 |
Employment Agreement, dated August 11, 2022, by and between the Registrant and Kamal Hamed Exhibit 10.5 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this ?Agreement?) is made and entered into this 4th day of August 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc., a Delaware corporation (?Company?), and Kamal Hamed (?Executive?). WHEREAS, Executive and Company desire to set forth the terms and conditions for the employment of the Executive by th |
|
| November 14, 2022 |
Exhibit 10.10 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment to Executive Employment Agreement (the ?Amendment?) is made and entered effective as of November 10, 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc., a Delaware corporation (?Company?), and Tamara Joseph (?Executive?) (each a ?Party? and collectively, the ?Parties?). BACKGROUND WHEREAS, Company currently e |
|
| November 14, 2022 |
Exhibit 10.3 EXCLUSIVE LICENSE AGREEMENT BY AND BETWEEN Spero Therapeutics, INC. AND GlaxoSmithKline Intellectual Property (No. 3) Limited DATED AS OF SEPTEMBER 21, 2022 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. TABL |
|
| November 14, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Spero Theraputics, Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| November 8, 2022 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBr Pursuant to the agreement, Spero will be receiving a $66 million upfront payment, received a $9 million direct equity investment in shares of Spero common stock, and is eligible for potential future milestone payments and tiered royalties CAMBRIDGE, Mass., November 08, 2022 — Spero T |
|
| October 3, 2022 |
SPRO / Spero Therapeutics Inc / Aquilo Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 84833T103 (CUSIP Number) September 22, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| September 22, 2022 |
Exhibit 99.1 GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr The exclusive license allows GSK to commercialize tebipenem HBr in all territories, except Japan and certain other Asian countries Spero Therapeutics receives $66 million upfront, with potential for future milestone payments, and tiered royalties. GSK to purchase $9 million i |
|
| September 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commis |
|
| September 19, 2022 |
2017 Stock Incentive Plan, as amended. Exhibit 10.1 SPERO THERAPEUTICS, INC. AMENDED AND RESTATED 2017 STOCK INCENTIVE PLAN (As Amended on September 15, 2022) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2017 Stock Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commis |
|
| September 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| September 6, 2022 |
Exhibit 99.1 Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration Alignment with the FDA on a regulatory path forward for the continued development of tebipenem Hbr FDA feedback indicates positive results from a single additional Phase 3 clinical trial in patients with complicated urinary tract infection (cUTI), with supportiv |
|
| August 10, 2022 |
Consulting Agreement, dated May 3, 2022, by and between the Registrant and David Melnick, M.D. CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?) is dated May 3, 2022 and is effective as of July 3, 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc. |
|
| August 10, 2022 |
Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update Initiation of a Placebo-controlled Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Expected in 4Q 2022 Initiation of a Phase 2 Cross-indication Resistant Pathogen Trial of SPR206 Expected in 3Q 2023 Continued Engagement with FDA is Expected to Provide Key |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-38266 (Commission File Numb |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THER |
|
| August 10, 2022 |
Separation Agreement, dated May 3, 2022, by and between the Registrant and Cristina Larkin 675 Massachusetts Avenue, 14th Floor Cambridge, MA 02139 May 3, 2022 Ms. Cristina Larkin Dear Cristina: As was discussed with you, your employment with Spero Therapeutics, Inc. (the "Company") is ending. This letter is to summarize the terms of the separation package that the "Company is willing to offer you as a result of your separation from employment. Please read this letter agreement (the ?Le |
|
| August 10, 2022 |
Consulting Agreement, dated May 3, 2022, by and between the Registrant and Cristina Larkin CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?) is dated May 3, 2022 and is effective as of July 3, 2022 (the ?Effective Date?) by and between Spero Therapeutics, Inc. |
|
| August 10, 2022 |
Separation Agreement, dated May 3, 2022, by and between the Registrant and David Melnick, M.D. 675 Massachusetts Avenue, 14th Floor Cambridge, MA 02139 May 3, 2022 Dr. David Melnick Dear David: As was discussed with you, your employment with Spero Therapeutics, Inc. (the "Company") is ending. This letter is to summarize the terms of the separation package that the "Company is willing to offer you as a result of your separation from employment. Please read this letter agreement (the ?Letter |
|
| August 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| June 27, 2022 |
Exhibit 99.1 Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application CAMBRIDGE, Mass., June 27, 2022 ? Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipen |
|
| June 27, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| June 7, 2022 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| June 7, 2022 |
Exhibit 10.1 Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed or because it contains personally identifiable information omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. REVENUE INTEREST TERMINATION AGREEMENT This Revenue Interest |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission F |
|
| May 16, 2022 |
Exhibit 99.1 Spero Therapeutics Announces First Quarter 2022 Operating Results and Provides Business Update New Strategic Direction Focuses on Advancing the Clinical Stage Pipeline and Identifying Tebipenem?s Optimal Path to Value Creation Initiation of a Phase 2 Trial of SPR720 in Nontuberculous Mycobacterial-Pulmonary Disease Expected in 2H 2022 SPR206?s Phase 1 Data Support Further Development |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THE |
|
| May 3, 2022 |
Exhibit 99.1 Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline Announces Immediate Cessation of Tebipenem HBr Commercialization Initiatives; Company to Shift Focus to Advancement of SPR720 and SPR206 Spero to Explore Strategic Partnerships and Other Opportunities for Tebipenem HBr Conference Call and Live Webcast at 8:30 a.m. ET Today CAMB |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 7, 2022 |
Exhibit 99.1 Spero Therapeutics Tebipenem Pivoxil Hydrobromide Phase 3 Data Published in The New England Journal of Medicine CAMBRIDGE, Mass., April 6, 2022 ? Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced publication in The New England Journal of Medicine (NEJM) of the results from the Phase 3 ADAPT-PO clinical trial for its investigational oral carbapenem antibiotic, tebipenem pivoxil h |
|
| April 7, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2022 |
Non-Employee Director Compensation Policy, as amended SPERO THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY (Last amended December 14, 2021) The Board of Directors of Spero Therapeutics, Inc. (the ?Company?) has approved the following Non-Employee Director Compensation Policy (this ?Policy?), which establishes compensation to be paid to non-employee directors of the Company, effective upon the completion of the Company?s initial public o |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38266 SPERO THERAPEUT |
|
| March 31, 2022 |
Description of Registrant’s Securities Exhibit 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Spero Therapeutics, Inc. (the ?Company? or ?we?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). DESCRIPTION OF COMMON STOCK We are authorized to issue 120,000,000 shares of commo |
|
| March 31, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2022 |
Exhibit 99.1 Spero Therapeutics Announces Fourth Quarter and Full Year 2021 Operating Results and Provides Business Update Provides update on ongoing FDA review of Tebipenem HBr NDA Phase 2 trial of SPR720 in nontuberculous mycobacterial-pulmonary disease on track for initiation in 2H 2022 following lifting of FDA clinical hold Topline results from Phase 1 bronchoalveolar lavage trial support furt |
|
| March 9, 2022 |
SPRO / Spero Therapeutics Inc / Aquilo Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 84833T103 (CUSIP Number) January 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| February 16, 2022 |
Exhibit 99.1 Spero Therapeutics Announces Positive Topline Results from Phase 1 Bronchoalveolar Lavage Clinical Trial of SPR206, A Novel Intravenous Next Generation Polymyxin Antibiotic for the Treatment of Multi-drug Resistant Gram-Negative Infections in the Hospital Setting SPR206 shown to be well-tolerated; achieved lung exposures consistent with predicted therapeutic levels, when administered |
|
| February 14, 2022 |
SPRO / Spero Therapeutics Inc / Aquilo Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 84833T103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Spero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84833T103 (CUSIP Number) December |
|
| January 25, 2022 |
SPR720: First Novel Oral Candidate Designed to Treat NTM Infections Broad spectrum, oral candidate: applicable to both non-refractory and refractory patients Approximately 95,000 patients in US. |
|
| January 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| January 25, 2022 |
SPRO / Spero Therapeutics Inc / Atlas Venture Fund IX, L.P. - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 4)* spero therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 (Title of Class of Securities) 84833T103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this S |
|
| January 25, 2022 |
Corporate Presentation January 2022 Exhibit 99.1 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the potential approval by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr; the timing of launch of tebipenem HBr; future comme |
|
| January 19, 2022 |
Exhibit 99.1 Spero Therapeutics Awarded up to an Additional $12.9 Million by BARDA to Support the Development of Orally Administered Tebipenem Pivoxil in Pediatric Patients New award option exercised by BARDA brings the total potential funding from its existing contract with Spero up to $59.7 million CAMBRIDGE, Mass., January 19, 2022 ? Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that |
|
| January 19, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| January 4, 2022 |
Exhibit 99.1 Spero Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022 CAMBRIDGE, Mass., January 3, 2022 ? Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S |
|
| January 4, 2022 |
Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720 Exhibit 99.2 Spero Therapeutics Announces Lifting of FDA Clinical Trial Hold on SPR720 CAMBRIDGE, Mass., January 4, 2022 ? Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 2 trial of SPR720, Spero?s investigational oral product candidate being developed for nontuberculous mycobacterial (NTM) disease. |
|
| January 4, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO |
|
| November 10, 2021 |
Exhibit 99.1 Spero Therapeutics Announces Third Quarter 2021 Operating Results and Provides Business Update Submitted NDA to U.S. FDA for tebipenem HBr for the treatment of complicated urinary tract infections, including pyelonephritis Entered into a non-dilutive revenue interest financing agreement with HealthCare Royalty Partners? for up to $125 million Conference call and live webcast at 4:30 p |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commiss |
|
| October 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 27, 2021 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| October 28, 2021 |
Exhibit 99.1 Spero Therapeutics Submits New Drug Application to U.S. FDA for Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections including Pyelonephritis CAMBRIDGE, Mass., October 28, 2021 ? Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas in |
|
| October 12, 2021 |
Exhibit 99.1 Spero Therapeutics Appoints Kathleen Tregoning to its Board of Directors Ms. Tregoning brings more than two decades of experience in biotechnology and public policy to Spero?s Board CAMBRIDGE, Mass., October 12, 2021 ? Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in hig |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2021 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissi |
|
| September 30, 2021 |
Exhibit 10.2 EXECUTION VERSION SECURITY AGREEMENT This SECURITY AGREEMENT, dated as of September 29, 2021 (as amended, restated, supplemented and otherwise modified from time to time, this ?Security Agreement?), is by and among the parties identified as ?Grantor? on the signature pages hereto and such other entities as may become ?Grantor? hereunder after the date hereof (collectively, the ?Granto |
|
| September 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 (September 29, 2021) SPERO THERAPEUTICS, INC. (Exact Name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of i |
|
| September 30, 2021 |
Exhibit 10.1 Certain information has been omitted from this exhibit in places marked ?[***]? because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed or because it contains personally identifiable information omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K. Execution Version REVENUE INTEREST FINANCING AGREEMENT betwee |
|
| September 20, 2021 |
As filed with the Securities and Exchange Commission on September 20, 2021 As filed with the Securities and Exchange Commission on September 20, 2021 Registration No. |
|
| September 20, 2021 |
Form of Stock Option Agreement under the 2017 Stock Incentive Plan, as amended. Exhibit 4.6 Option No. SPERO THERAPEUTICS, INC. Stock Option Grant Notice Stock Option Grant under the Company?s 2017 Stock Incentive Plan (As Amended on August 17, 2021) 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per share: 6. Option Expiration Date: 7. Vesting Start |
|
| September 16, 2021 |
SPRO / Spero Therapeutics Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 6)* SPERO THERAPEUTICS, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 84833T 10 3 (CUSIP Num |
|
| August 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2021 SPERO THERAPEUTICS, INC. (Exact Name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| August 30, 2021 |
Form of Restricted Stock Unit Agreement under the 2017 Stock Incentive Plan, as amended. Exhibit 10.1 Restricted Stock Unit No. SPERO THERAPEUTICS, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company?s 2017 Stock Incentive Plan (As Amended on August 17, 2021) 1. Name and Address of Participant: 2. Date of Grant of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Rest |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2021 SPERO THERAPEUTICS, INC. (Exact Name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commissio |
|
| August 18, 2021 |
2017 Stock Incentive Plan, as amended. Exhibit 10.1 SPERO THERAPEUTICS, INC. AMENDED AND RESTATED 2017 STOCK INCENTIVE PLAN (As Amended on August 17, 2021) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Spero Therapeutics, Inc. 2017 Stock Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act |
|
| August 18, 2021 |
Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF SPERO THERAPEUTICS, INC. It is hereby certified that: FIRST: The name of the corporation is Spero Therapeutics, Inc. (the ?Corporation?). SECOND: The Restated Certificate of Incorporation of the Corporation, filed on November 6, 2017 (the ?Restated Certificate of Incorporation?) is hereby amended, effective as of Augu |
|
| August 5, 2021 |
Share Purchase Agreement, dated June 30, 2021, by and between the Registrant and Pfizer Inc. Exhibit 10.2 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this ?Agreement?) dated as of June 30, 2021 (the ?Effective Date?) is made by and between Spero Therapeutics, Inc., a Delaware corporation (the ?Company?), and Pfizer Inc., a Delaware corporation (the ?Purchaser?). WHEREAS, the Company and the Purchaser are executing and delivering this Agreement in reliance upon the exemption fr |
|
| August 5, 2021 |
License Agreement, dated June 30, 2021, by and between the Registrant and Pfizer Inc. Exhibit 10.1 LICENSE AGREEMENT by and among SPERO THERAPEUTICS, INC. and Pfizer inc. June 30, 2021 [***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 5 ARTICLE 2 LICENSES 22 2.1 Licenses to Pfi |
|
| August 5, 2021 |
Exhibit 99.1 Spero Therapeutics Announces Second Quarter 2021 Operating Results and Provides Business Update Tebipenem HBr on track for NDA submission in the fourth quarter of 2021 Announced $40 million equity investment from Pfizer Inc. and licensing agreement for SPR206 Initiated Phase 1 bronchoalveolar lavage and renal impairment clinical trials of SPR206 Conference call and live webcast at 4:3 |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THER |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| July 9, 2021 |
SPRO / Spero Therapeutics Inc / PFIZER INC - SC 13G SPERO THERAPEUTICS, INC. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Spero Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 84833T103 (CUSIP Number) June 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| July 6, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| July 1, 2021 |
Exhibit 99.1 Spero Therapeutics Announces $40 Million Equity Investment from Pfizer Inc. and Licensing Agreement for SPR206 Spero grants Pfizer rights to develop, manufacture, and commercialize SPR206 in ex-U.S. and ex-Asia territories in exchange for potential development and commercial milestone payments and royalties. CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) ? Spero Therapeutics, Inc. ( |
|
| July 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2021 SPERO THERAPEUTICS, INC. (Exact Name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| June 25, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2021 |
Quarterly Report - 10-Q Q1 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38266 SPERO THE |
|
| May 6, 2021 |
Exhibit 99.1 Spero Therapeutics Announces First Quarter 2021 Operating Results and Provides Business Update Tebipenem HBr remains on track for NDA submission in the second half of 2021 Conference call and live webcast at 4:30 p.m. ET today CAMBRIDGE, Mass., May 6, 2021 ? Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developi |
|
| March 24, 2021 |
Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 Spero Therapeutics, Inc. 675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts 02139 March 24, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell RE: Spero Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-254170 Request for Acceleration of Effectiveness Ladies a |
|
| March 23, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| March 11, 2021 |
EX-99.1 Exhibit 99.1 Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update Tebipenem HBr advancing towards NDA submission in the second half of 2021 Conference call and live webcast at 4:30 p.m. EST today CAMBRIDGE, Mass., March 11, 2021 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 SPERO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38266 46-4590683 (State or other jurisdiction of incorporation) (Commission |
|
| March 11, 2021 |
Exhibit 10.25 AMENDED AND RESTATED LICENSE AGREEMENT This AMENDED AND RESTATED LICENSE AGREEMENT (this ?Agreement?) , effective as of January 15, 2021 (the ?Amendment Effective Date?), is entered into by and among Everest Medicines II Limited, a company incorporated under the laws of the Cayman Islands (?Everest?) having its registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavi |
